Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H31NO3.ClH |
| Molecular Weight | 393.947 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)C2=CC=CC=C2
InChI
InChIKey=SWIJYDAEGSIQPZ-FTBISJDPSA-N
InChI=1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H/t22-;/m0./s1
| Molecular Formula | C22H31NO3 |
| Molecular Weight | 357.4864 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Tolterodine: a review of its use in the treatment of overactive bladder. | 2001 |
|
| Preformulation studies on the S-isomer of oxybutynin hydrochloride, an Improved Chemical Entity (ICE). | 2001 Apr |
|
| Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. | 2001 Oct |
|
| Augmentation ureterocystoplasty in bladder exstrophy: 5-year follow-up in two cases. | 2002 Dec |
|
| Oxytrol approved for overactive bladder. | 2003 Aug |
|
| [Non-coordinated micturition syndrome mimicking posterior urethral valves in a male neonate]. | 2003 Jul |
|
| Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. | 2003 Jun |
|
| Oxybutynin transdermal (Oxytrol) for overactive bladder. | 2003 May 12 |
|
| Acupressure versus oxybutinin in the treatment of enuresis. | 2003 Nov-Dec |
|
| [Prevalence of urinary incontinence and linked factors in men and women over 65]. | 2003 Oct 15 |
|
| Oxybutynin extended-release: a review of its use in the management of overactive bladder. | 2004 |
|
| Drug approval highlights for 2003. | 2004 Feb |
|
| A population pharmacokinetic model with time-dependent covariates measured with errors. | 2004 Jun |
|
| Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review. | 2004 Nov |
|
| Rapid and selective UV spectrophotometric and RP-HPLC methods for dissolution studies of oxybutynin immediate-release and controlled-release formulations. | 2004 Nov 15 |
|
| Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. | 2004 Oct |
|
| [Urinary incontinence: anticholinergic treatment]. | 2004 Oct-Dec |
|
| High performance liquid chromatographic determination of oxeladin citrate and oxybutynin hydrochloride and their degradation products. | 2005 Aug |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
| Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices. | 2005 Mar 21 |
|
| Canadian Urological Association guidelines on urinary incontinence. | 2006 Jun |
|
| Pharmacologic management of overactive bladder. | 2007 |
|
| Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin. | 2007 Jul 13 |
|
| Bladder augmentation: Review of the literature and recent advances. | 2007 Oct |
|
| A review of urodynamic evaluation in children and its role in the management of boys with posterior urethral valves. | 2007 Oct |
|
| Intravesical treatments for painful bladder syndrome/ interstitial cystitis. | 2007 Oct 17 |
|
| Bladder dysfunction and vesicoureteral reflux. | 2008 |
|
| Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin. | 2008 Feb 2 |
|
| Treatment of urinary incontinence after stroke in adults. | 2008 Jan 23 |
|
| Polymeric matrix membrane sensors for stability-indicating potentiometric determination of oxybutynin hydrochloride and flavoxate hydrochloride urogenital system drugs. | 2008 Nov-Dec |
|
| Locked-in Syndrome in a Nigerian male with Multiple Sclerosis: a case report and literature review. | 2008 Oct 30 |
|
| Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction. | 2009 |
|
| No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot study. | 2009 Dec 14 |
|
| Oxybutynin extended release for the management of overactive bladder: a clinical review. | 2009 Sep 21 |
|
| Anesthetic management of the emergency laparotomy for a patient with multiple sclerosis -A case report-. | 2010 Nov |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:17:28 GMT 2023
by
admin
on
Sat Dec 16 11:17:28 GMT 2023
|
| Record UNII |
JWB87T68BN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11349918
Created by
admin on Sat Dec 16 11:17:28 GMT 2023 , Edited by admin on Sat Dec 16 11:17:28 GMT 2023
|
PRIMARY | |||
|
JWB87T68BN
Created by
admin on Sat Dec 16 11:17:28 GMT 2023 , Edited by admin on Sat Dec 16 11:17:28 GMT 2023
|
PRIMARY | |||
|
1207344-05-5
Created by
admin on Sat Dec 16 11:17:28 GMT 2023 , Edited by admin on Sat Dec 16 11:17:28 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
|
